Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis

Autor: Josephine Harrington, Anne S. Hellkamp, Kenneth W. Mahaffey, Günter Breithardt, Jonathan L. Halperin, Graeme J. Hankey, Richard C. Becker, Christopher C. Nessel, Scott D. Berkowitz, Keith A. A. Fox, Daniel E. Singer, Shaun G. Goodman, Manesh R. Patel, Jonathan P. Piccini

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 11 (2024)

Background Days alive out of hospital (DAOH) is an objective and patient‐centered net benefit end point. There are no assessments of DAOH in clinical trials of interventions for atrial fibrillation (AF), and it is not known whether this end point i

Externí odkaz: https://doaj.org/article/a5fb44f1354d4d29a8e3aab8c544798b

Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial

Autor: Anthony P. Carnicelli, Anne S. Hellkamp, Kenneth W. Mahaffey, Daniel E. Singer, Günter Breithardt, Jonathan L. Halperin, Graeme J. Hankey, Jonathan P. Piccini, Richard C. Becker, Christopher C. Nessel, Scott D. Berkowitz, Keith A. A. Fox, Robert M. Califf, Manesh R. Patel

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 19 (2021)

Background In event‐driven clinical trials, study termination is based on accrual of a target number of primary efficacy events. For noninferiority trials in which superiority is conditionally examined, the ideal cohort in which to track event accr

Externí odkaz: https://doaj.org/article/775fd7c4e9564bab97ecb1aeeaaa5927

Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden

Autor: Andreas Rillig, Katrin Borof, Günter Breithardt, A. John Camm, Harry J.G.M. Crijns, Andreas Goette, Karl-Heinz Kuck, Andreas Metzner, Panos Vardas, Eik Vettorazzi, Karl Wegscheider, Antonia Zapf, Paulus Kirchhof

Publikováno v: Circulation, 146(11), 836-847. LIPPINCOTT WILLIAMS & WILKINS

Background: The randomized EAST-AFNET4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial–Atrial Fibrillation Network) demonstrated that early rhythm control (ERC) reduces adverse cardiovascular outcomes in patients with recently d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f09ae66be49001d2b31453187f2eb887
https://doi.org/10.1161/circulationaha.122.060274

Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms

Autor: Renate B. Schnabel, Isabelle C. Van Gelder, Lukasz Szumowski, Harry J.G.M. Crijns, Günter Breithardt, Sakis Themistoclakis, Karl Wegscheider, Stephan Willems, G. André Ng, Axel Brandes, Laurent M. Haegeli, Hein Heidbuchel, Anna Suling, Panos E. Vardas, Nele Gessler, Katrin Borof, A. John Camm, Paulus Kirchhof, Andreas Goette, Lars Eckardt, Josef Kautzner

Publikováno v: European heart journal
Willems, S, Borof, K, Brandes, A, Breithardt, G, Camm, A J, Crijns, H J G M, Eckardt, L, Gessler, N, Goette, A, Haegeli, L M, Heidbuchel, H, Kautzner, J, Ng, G A, Schnabel, R B, Suling, A, Szumowski, L, Themistoclakis, S, Vardas, P, van Gelder, I C, Wegscheider, K & Kirchhof, P 2022, ' Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms : the EAST-AFNET 4 trial ', European Heart Journal, vol. 43, no. 12, pp. 1219-1230 . https://doi.org/10.1093/eurheartj/ehab593
European Heart Journal, 43(12), 1219-1230. Oxford University Press

Aims Clinical practice guidelines restrict rhythm control therapy to patients with symptomatic atrial fibrillation (AF). The EAST-AFNET 4 trial demonstrated that early, systematic rhythm control improves clinical outcomes compared to symptom-directed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a94733b570366b41d2a043da473e1b1e
https://doi.org/10.1093/eurheartj/ehab593

Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure

Autor: Karl Wegscheider, Christina Magnussen, Paulus Kirchhof, Anna Suling, Ann-Kathrin Ozga, Isabelle C. Van Gelder, Harry J.G.M. Crijns, Andreas Goette, Günter Breithardt, Karl-Heinz Kuck, Michele Massimo Gulizia, Axel Brandes, Lukasz Szumowski, Andreas Rillig, Arif Elvan, A. John Camm, Hein Heidbuchel, Andre Ng, Laurent M. Haegeli, Lars Eckardt

Publikováno v: Rillig, A, Magnussen, C, Ozga, A-K, Suling, A, Brandes, A, Breithardt, G, Camm, A J, Crijns, H J G M, Eckardt, L, Elvan, A, Goette, A, Gulizia, M, Haegeli, L, Heidbuchel, H, Kuck, K-H, Ng, A, Szumowski, L, van Gelder, I, Wegscheider, K & Kirchhof, P 2021, ' Early Rhythm Control Therapy in Patients with Atrial Fibrillation and Heart Failure ', Circulation, vol. 144, no. 11, pp. 845-858 . https://doi.org/10.1161/CIRCULATIONAHA.121.056323
Circulation, 144(11), 845-858. LIPPINCOTT WILLIAMS & WILKINS
Circulation

Supplemental Digital Content is available in the text.
Background: Even on optimal therapy, many patients with heart failure and atrial fibrillation experience cardiovascular complications. Additional treatments are needed to reduce these events

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04360aeefd4484cae7caae1bbfe1ce36
https://doi.org/10.1161/circulationaha.121.056323